The company is undertaking development of its first drug candidate and its companion diagnostic in oncology.
PEP-Therapy, a biotechnology company developing targeted therapies for cancer treatments, has raised €1.3 million in initial fund ing. This sum, invested by the Quadrivium 1 seed fund and a business angel, Dr Bernard Majoie, will enable PEP-Therapy to undertake regulatory development of its first therapeutic product, associated with a predictive biomarker for foreseeing the effectiveness of the treatment. The product relies on the innovative technology of bi-functional peptides, which penetrate cells and then specifically block pathological mechanisms, without affecting normal physiological mechanisms.